Ibrexafungerp

Ibrexafungerp is a prescription medication used for the treatment of vulvovaginal candidiasis.

• Ibrexafungerp is available under the following different brand names: Brexafemme

Adult and pediatric dosage

Tablet

• 150mg

Vulvovaginal candidiasis

Adult and postmenarchal female dosage

• 300 mg orally twice a day for a day
• Total treatment dosage: 600 mg.

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

Common side effects of Ibrexafungerp include:

• diarrhea,
• nausea,
• abdominal pain,
• dizziness,
• vomiting,
• painful menstrual periods,
• gas (flatulence),
• back pain,
• elevated transaminases,
• vaginal bleeding, and
• rash/hypersensitivity reaction.

Serious side effects of Ibrexafungerp include:

• rash, 
• itching/swelling (especially of the face/tongue/throat), 
• severe dizziness, and
• trouble breathing.

Rare side effects of Ibrexafungerp include:

• none 

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first

• Ibrexafungerp has severe interactions with no other drugs.
• Ibrexafungerp has serious interactions with the following drugs:
  • mobocertinib
  • pacritinib
• Ibrexafungerp has moderate interactions with the following drugs:
  • atogepant
  • daridorexant
  • finerenone
  • isavuconazonium sulfate
  • voclosporin
• Ibrexafungerp has minor interactions with no other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns.

Contraindications

• Pregnancy
• Hypersensitivity to ibrexafungerp

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Ibrexafungerp?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Ibrexafungerp?”

Cautions

• Contraindicated to pregnancy; based on animal data, fetal harm may occur

Drug interaction overview

• CYP3A4 substrate
  • Inhibitor of CYP3A4, P-gp, and OATP1B3 transporter
  • Strong CYP3A4 inhibitors
    • Reduce ibrexafungerp dose
    • Strong CYP3A inhibitors increase the exposure of ibrexafungerp
• Strong and moderate CYP3A inducers
  • Avoid coadministration
  • Strong and moderate CYP3A inducers may significantly reduce the exposure of ibrexafungerp

Pregnancy and Lactation

Contraindicated

• Insufficient data are available on use in pregnant females on any drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes
• Verify pregnancy status in females of reproductive potential before initiating treatment
• If inadvertently administered during pregnancy or if pregnancy is detected within 4 days after receiving therapy, pregnant females exposed and healthcare providers should report pregnancies to SCYNEXIS, Inc. at 1-888-982-SCYX (7299)

Contraception

• Females of reproductive potential: Use effective contraception during treatment and for 4 days after the final dose

Lactation

• No data are available on drug presence in either human or animal milk, effects on breastfed infants, or effects on milk production